Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein
Open Access
- 23 June 2006
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (1), 97-112
- https://doi.org/10.1111/j.1365-2125.2006.02719.x
Abstract
Aims The aims of this observational study were to assess the variability in imatinib pharmacokinetics and to explore the relationship between its disposition and various biological covariates, especially plasma α1-acid glycoprotein concentrations. Methods A population pharmacokinetic analysis was performed using NONMEM based on 321 plasma samples from 59 patients with either chronic myeloid leukaemia or gastrointestinal stromal tumours. The influence of covariates on oral clearance and volume of distribution was examined. Furthermore, the in vivo intracellular pharmacokinetics of imatinib was explored in five patients. Results A one-compartment model with first-order absorption appropriately described the data, giving a mean (± SEM) oral clearance of 14.3 l h−1 (± 1.0) and a volume of distribution of 347 l (± 62). Oral clearance was influenced by body weight, age, sex and disease diagnosis. A large proportion of the interindividual variability (36% of clearance and 63% of volume of distribution) remained unexplained by these demographic covariates. Plasma α1-acid glycoprotein concentrations had a marked influence on total imatinib concentrations. Moreover, we observed an intra/extracellular ratio of 8, suggesting substantial uptake of the drug into the target cells. Conclusion Because of the high pharmacokinetic variability of imatinib and the reported relationships between its plasma concentration and efficacy and toxicity, the usefulness of therapeutic drug monitoring as an aid to optimizing therapy should be further investigated. Ideally, such an approach should take account of either circulating α1-acid glycoprotein concentrations or free imatinib concentrations.Keywords
This publication has 63 references indexed in Scilit:
- Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mgEuropean Journal Of Cancer, 2005
- METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERSPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug ResistanceClinical Pharmacokinetics, 2005
- Clinical Pharmacokinetics of ImatinibClinical Pharmacokinetics, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Disposition of sulfadimethoxine in swine: Inclusion of protein binding factors in a pharmacokinetic modelJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974